Illumina (ILMN) Receives Analyst Rating

Illumina (ILMN) : The consensus on Illumina (ILMN) based on 15 analyst recommendation on the company stock is 2.55, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 2 which endorses a Buy on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Illumina (ILMN) : The highest level Illumina (ILMN) is projected to reach is $180 for the short term and the lowest estimate is at $115. The consolidated price target from 10 rating analysts who initiate coverage on the stock is $152.1 and the possibility the share price can swing is $20.63.


Also, Brokerage firm CL King downgrades its rating on Illumina (NASDAQ:ILMN). The shares have been rated Neutral. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 22, 2016.

Illumina (NASDAQ:ILMN): After opening at $171.37, the stock dipped to an intraday low of $169.61 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $175.24 and the buying power remained strong till the end. The stock closed at $174.94 for the day, a gain of 1.84% for the day session. The total traded volume was 915,043. The stocks close on the previous trading day was $171.78.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.